Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06677710 is registered in ClinicalTrials.gov with Indapta Therapeutics, INC. as lead sponsor.

NCT NCT06677710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
Lead sponsor
Indapta Therapeutics, INC.
Phase
Phase 1
Overall status
Suspended
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
34 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, autoimmune diseases of the nervous system, demyelinating autoimmune diseases, central nervous system (cns), demyelinating diseases, immune system diseases, multiple sclerosis, nervous system diseases, non-active secondary progressive multiple sclerosis, non-active spms, primary progressive multiple sclerosis (ppms), secondary progressive multiple sclerosis (spms)